138MO Prognostic performance of Breast Cancer Index (BCI) in postmenopausal women with early-stage HR+ breast cancer in the TEAM trial

J.M Bartlett,C Markopoulos,M Spears,J Wong,A Hasenburg,D Rea,L.Y Dirix,Y Zhang,G Pond,R Salunga,C Van De Velde,K Treuner,K.J Taylor,C Seynaeve,J Bayani,E Mallon,C.A Schnabel,K Xu

doi:10.1016/j.annonc.2022.07.173

Abstract

Early-stage HR+ breast cancer patients face a prolonged risk of recurrence even after adjuvant endocrine therapy. The Breast Cancer Index (BCI) and BCIN+ prognostic models are significantly prognostic for risk of overall (0-10y) and late (5-10y) distant recurrence (DR) in N0 and N1 breast cancer, respectively. Here, the prognostic performance of BCI and BCIN+ was evaluated in a cohort of HR+ postmenopausal women from the Tamoxifen and Exemestane Adjuvant Multinational (TEAM) trial.

Full Text